Work

Summary of the IC50s of Delta-24-RGD in Tested Pancreatic Cancer Cell Lines from Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma

Year: 2023

Type: other

Abstract: This table summarizes the dose (multiplicity of infection, MOI) of Delta-24-RGD that causes 50% of viability inhibition of infected pancreatic cancer cell lines (IC50).

DOI: 10.1158/1535-7163.22508170.v1

Authors: Bingbing Dai, David Roife, Ya'an Kang, Joy Gumin, Mayrim V. Rios Perez, Xinqun Li, Michael Pratt, Rolf A. Brekken, Juan Fueyo-Margareto, Frederick F. Lang, Jason B. Fleming

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362535026

Cites:

Cited by:

Related to: 10